key: cord-0960600-9ygjzz6d
authors: Wall, Emma C.; Chan, Jia Mun; Gil, Eliza; Heyderman, Robert S.
title: Acute bacterial meningitis
date: 2021-03-26
journal: Curr Opin Neurol
DOI: 10.1097/wco.0000000000000934
sha: 974495caea2dfc83ef20ed8801eac7bd71783536
doc_id: 960600
cord_uid: 9ygjzz6d

PURPOSE OF REVIEW: Community-acquired bacterial meningitis is a continually changing disease. This review summarises both dynamic epidemiology and emerging data on pathogenesis. Updated clinical guidelines are discussed, new agents undergoing clinical trials intended to reduce secondary brain damage are presented. RECENT FINDINGS: Conjugate vaccines are effective against serotype/serogroup-specific meningitis but vaccine escape variants are rising in prevalence. Meningitis occurs when bacteria evade mucosal and circulating immune responses and invade the brain: directly, or across the blood–brain barrier. Tissue damage is caused when host genetic susceptibility is exploited by bacterial virulence. The classical clinical triad of fever, neck stiffness and headache has poor diagnostic sensitivity, all guidelines reflect the necessity for a low index of suspicion and early Lumbar puncture. Unnecessary cranial imaging causes diagnostic delays. cerebrospinal fluid (CSF) culture and PCR are diagnostic, direct next-generation sequencing of CSF may revolutionise diagnostics. Administration of early antibiotics is essential to improve survival. Dexamethasone partially mitigates central nervous system inflammation in high-income settings. New agents in clinical trials include C5 inhibitors and daptomycin, data are expected in 2025. SUMMARY: Clinicians must remain vigilant for bacterial meningitis. Constantly changing epidemiology and emerging pathogenesis data are increasing the understanding of meningitis. Prospects for better treatments are forthcoming.

Acute bacterial meningitis (ABM) is a disease with rapid onset, outbreak and epidemic potential, and high rates of mortality and morbidity [1, 2] . Considerable advances have been made in the last 30 years towards epidemic management and disease control through vaccination, and understanding the contributions of both host and pathogen to clinical outcomes. In this review, we will summarise the rapidly changing epidemiology of ABM in the context of new vaccines. We will show how new unbiased genomics technologies are revealing specific host-pathogen interactions that cause inflammation and brain damage. Additionally, we will summarise which new adjunctive treatments are in development and describe how the current Severe Acute Respiratory Syndrome CoronaVirus2 (SARS-CoV2) pandemic may impact on the WHO's efforts to defeat meningitis by 2030.

Community-acquired bacterial meningitis is predominately caused by three pathogens, Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus influenzae type B. Additionally, Streptococcus suis in Southeast Asia, Listeria monocytogenes, Group B Streptococci, and Gram-negative bacteria such as Escherichia coli and Klebsiella pneumoniae, cause meningitis in specific groups, including neonates, pregnant women, transplant recipients and older adults [3] . Worldwide, the number of reported cases of bacterial meningitis to global surveillance sites rose between 2006 and 2016, with incidence strongly related to poverty (SDI) [3] . However, the geographical incidence varies significantly. In well-resourced settings, ABM incidence has fallen to below 0.5-1.5/ 100 000 population [4,5,6 && ]. Contrastingly, in countries in the African Sahel region, where epidemic meningitis due to N. meningitidis and S. pneumoniae persists, incidence reaches 1000/100 000 cases [3,7-9]. Beyond the meningitis belt, the incidence in Africa approaches 2.5-25/100 000 per population [10, 11] .

Bacterial meningitis is globally associated with cooler, drier seasons [9] . It is likely that climate change will impact on meningitis incidence but modelling data are lacking [11] . Social distancing measures introduced to mitigate the spread of SARS-CoV2 during the CoronaVirus Infectious Diseases 2019 pandemic are also predicted to lead to a 20-30% decrease in meningitis incidence [12 & ,13] . Global meningitis epidemiology is highly dynamic; changes in the last 25 years amongst adults and children have been influenced by the widespread use of conjugate vaccines [14] [15] [16] , the HIV-1 epidemic [17] [18] [19] , the roll-out of antiretroviral and antibacterial treatment including prevention of mother-to-child transmission [20, 21] , and significant progress on development and poverty reduction strategies (SDG), including improved maternal and neonatal care [22] .

Vaccination remains the most important pillar of the WHO-led roadmap towards defeating meningitis by 2030 [23] . A summary of all available vaccines against the three common pathogens is given in Table 1 .

S. pneumoniae is the commonest cause of ABM world-wide. Reports of reduction in paediatric invasive pneumococcal disease (IPD), following pneumococcal conjugate vaccine introduction in higherincome countries, were rapidly followed by evidence of herd immunity in the wider adult population, particularly the elderly [24] [25] [26] . Incidence of S. pneumoniae meningitis is estimated to have fallen by 48% in children [14, 16, 27] . However, parallel reports have emerged of IPD, including meningitis, caused by nonvaccine serotypes [14, [28] [29] [30] . To mitigate against serotype replacement and better prevent meningitis, new approaches to pneumococcal vaccine design are under development, including whole capsule and protein vaccines [31] [32] [33] [34] 35 & ].

Conjugate meningococcal vaccines are highly effective in preventing meningitis caused by individual serogroups. Serogroup C Incidence has declined dramatically following the introduction of Men-C vaccine in children in many high-income countries [36] [37] [38] . Epidemic meningitis caused by serogroup A in the Sahel region of Africa has been dramatically reduced by low-cost MenAfriVac serogroup A conjugate vaccine by 92% [39, 40] . However, virulent clones of other serogroups have subsequently emerged (C, W, X) and epidemics of meningococcal meningitis continue to occur in the Sahel [41, 42] . As serogroup C disease declined, serogroup B emerged as the leading cause of meningococcal meningitis in high SDI countries [15] . In 2015, the UK government introduced protein-based serogroup B vaccine 4CMenB (Bexsero) to all children under 2 years. UK cases of invasive serogroup B in children have declined 75% with an estimated overall vaccine efficacy of 54% [43] . However, disease due to other serogroups including W and Y remains problematic. MenC conjugate vaccine has now been replaced with quadrivalent MenACWY vaccine for all teenagers and young adults in the UK [38] .

Hib vaccination in 1989 led to dramatic reductions in paediatric meningitis between 75 and 95% [44, 45] . Subsequently, Hib meningitis has virtually been eliminated globally in countries with effective Expanded Programme of Immunisations (EPI), but persists where vaccination coverage is poor including India, Nigeria, Pakistan and the Democratic Republic of Congo [16, 44, 46, 47] . Hib conjugate vaccines are estimated to have reduced Hib meningitis by 49% globally 2000-2016 [3], and paediatric

The epidemiology of bacterial meningitis is regional and highly dynamic, influenced by vaccines, climate, latitude, population movement, viral infections and poverty.

Serotype/serogroup specific conjugate vaccines are highly effective in preventing meningitis, but serotype replacement is increasing, effectively limiting the impact of conjugate vaccines on disease incidence Host and pathogen factors influence clinical outcomes, host genetic susceptibility to poor outcome from pneumococcal meningitis is linked to genes involved in NF-kB signalling and endothelial integrity.

Dexamethasone improves outcome in pneumococcal meningitis in high-income settings only, new agents targeted on the host response are currently in clinical trials.

Streptococcus agalactiae (Group B Streptococcus, GBS) primarily causes meningitis in neonates but also causes sepsis in older adults with co-morbidities and young adults who have consumed contaminated fish [48] . Serotypes Ia, Ib, II, III and V account for 98% of human carriage serotypes isolated globally [49] . Clonal complex 17 (CC17) strains have been shown to be hypervirulent, accounting for more than 80% of the disease [50, 51] . GBS disease-causing lineages have distinct niche adaptation and virulence characteristics [52, 53] . The most promising strategy to eliminate neonatal meningitis caused by GBS is vaccination in pregnancy, trials are ongoing [54] [55] [56] [57] .

The pathogenesis of most ABM follows a sequential pattern: nasopharyngeal colonization, bloodstream invasion across the mucosa, circulation of bacteria to the central nervous system (CNS), and subsequent CNS entry [58 & ,59] . In ABM caused by L. monocytogenes, GBS and S. suis, bacteraemia has a gastrointestinal or genitourinary tract source [52, 60, 61] . Occasionally, ABM is acquired through direct CNS invasion through the cribriform plate [62, 63] . In the majority of immunocompetent individuals, colonisation of the nasopharynx by S. pneumoniae and N. meningitidis is cleared by mucosal immunity, despite epithelial invasion [58 & ]. Coinfection with S. pneumoniae and respiratory viruses such as influenza causes a heightened inflammatory state associated with both pneumococcal and meningococcal invasion [64] [65] [66] , indeed preceding influenza is associated with seasonal ABM [11, 67 & ]. Bacteraemia usually precedes translocation across the blood-brain barrier (BBB) and/or blood-cerebrospinal fluid barrier into the CNS. Under basal conditions, the CNS environment is under continuous immunological surveillance [68] . This is achieved through the complexity of the BBB, where pericytes, astrocytes, microglia and specialised endothelial cells work in synergy to both resist pathogen invasion and kill bacteria on entry [68] (Fig. 1) . Bacteria breach the BBB by interacting with laminin receptors and exploiting endocytic pathways, for example via Platelet Activating Factor Receptor signalling [69] [70] [71] [72] (Fig. 1 ). However, mechanisms by which ABM-causing bacteria subvert CNS barriers to cause meningitis are not fully described.

In the 10-30% of ABM cases without concurrent bacteraemia [73] , bacteria may interact with gangliosides, adhere to the olfactory bulb, invade the olfactory epithelium and directly translocate to the brain [63, [74] [75] [76] [77] . Pneumococcal strains causing nonhematogenous meningitis tend to be less frequently studied using bacteraemia-based animal models [75] [76] [77] .

Bacteria replicate rapidly in the relatively immuneprivileged CNS compartment [78] , releasing Pathogen Associated Molecular Pattern (PAMP)s that bind to toll-like receptors including 2,3,4 and 9, triggering the release of Damage-Accoiated Molecular Pattern Signallings (DAMPs) via Nuclear Factor Kappa-light-chain-enhancer of activated B cells (NF-kB) activation [79] [80] [81] [82] Host-detection of bacteria within the CNS triggers a highly inflammatory, and predominately ineffective host response, associated with further tissue damage. Sustained inflammation exacerbates tissue damage, leading to death or irreversible neurological damage [73, 90, 91] . Neutrophil infiltration is important for bacterial elimination [92] Clinical improvement with dexamethasone adjunctive therapy in both Hib and pneumococcal meningitis demonstrates the importance of hostmediated inflammation in ABM [99, 100] . Dexamethasone may reduce NF-kB signalling and cytokine release [101] .

Bacterial genome-wide association studies (GWAS) have revealed loci that are implicated in invasiveness, tissue tropism and the ability to cause CNS disease [102 && ,103 && , 104, 105] . Single Nucleotide Polymorphisms (SNPs) in the raf operon determine pneumococcal tropism for ear/brain or lungs in an intranasal challenge model [106 & ,107] . Additionally, SNPs in raf modulated neutrophil recruitment, leading to strain-dependent clearance [106 & ]. Gene expression in S. pneumoniae is niche dependent, highlighting the importance of bacterial metabolism in pathogenesis [108,109 && ]. In a quantitative proteomics study of ABM, the abundance of pneumococcal protein Elongation Factor Tu in CSF associated with severity in human disease [97 & ]. In a murine model, proteins AliB and competence peptides were implicated in pathogenesis [110] . Joint human-pathogen GWAS studies of meningitis patients suggest that genetic differences in the host response exert greater effects on susceptibility and disease severity than bacterial genotype. This GWAS identified variants in the CCDC3 gene associated with disease severity [102 && ]. CCDC3 is a multifunction gene involved in the metabolism and suppression of NF-kB-TNFa activation in endothelial cells [111] .

Early recognition and initiation of appropriate antimicrobials are essential to minimise death and complications from ABM. The differential diagnosis in patients presenting with headache, fever, neck stiffness or altered mental state is broad: the classical meningitis triad has limited diagnostic sensitivity [112] . A high index of clinical suspicion is thus required to diagnose ABM [113] . Lumbar puncture is essential, and should be undertaken promptly before CSF is rendered sterile by broad-spectrum antibiotics [114] .

Many patients with ABM present with an altered level of consciousness, leading clinicians to frequently request cranial imaging prior to diagnostic lumbar puncture. Early Lumbar puncture (LP) is strongly associated with higher diagnostic yield from the CSF; delays in LP for cranial imaging lead to substantial reductions in yield from either CSF bacterial culture or PCR [114] . Delays to diagnosis are linked to worse clinical outcomes [114] [115] [116] . Cranial imaging (either CT or MRI) in patients with clear clinical signs and symptoms of meningitis without focal neurology is thus not recommended in the majority of patients with suspected ABM [117, 118] . CT has poor inter-reporting reliability to predict the risk of cerebral herniation in ABM [119] . The American, British and European infection societies meningitis guidelines all recommend immediate LP in cases of suspected ABM without delay for CT/MRI in immunocompetent adults with suspected ABM who have a stable GCS of 12/15 without seizures [119] [120] [121] [122] [123] . Important contraindications to LP include shock, respiratory compromise, or coagulopathy.

The diagnosis of ABM is dependent on the analysis of CSF. The leukocyte count remains the strongest predictive value of ABM. Diagnostic models including clinical, CSF and blood data show little additional benefit beyond clinical judgement [111] . Antibiotic administration prior to LP commonly renders the CSF sterile, thus clinicians are increasingly dependent on diagnostic PCR. Recent data suggest that while small multiplex panels targeting Hib, meningococci and pneumococci are highly sensitive and specific [123] , larger panels that include viral, nosocomial and rarer communityacquired pathogens have varying sensitivity and specificity and are not currently recommended [124] . More recently, direct next-generation sequencing (NGS) and metagenomics of CSF have been proposed to detect pathogens in cases with a high index of clinical suspicion of ABM but negative PCR tests [125 && ]. While this approach is promising, constraints around cost, bioinformatics expertise and clinically relevant turnaround times have limited clinical use of NGS to date [124] . All guidelines recommend patients with suspected ABM should receive parenteral antibiotics within 1 h. However, only 46% of patients in a clinical research study were reported to meet this target, limited by delays in the emergency department [126, 127] . Antibiotic choice should be determined by patient risk group, patient allergies, and local guidelines informed by epidemiology, including antimicrobial resistance. Penicillin resistance in S. pneumoniae is 15-20% in some settings, but remains <5% in N. meningitidis [128, 129] . However, quinolone resistance in N. meningitidis reaches 70% in Southeast Asia [15, 130] . Diagnostic uncertainty in culture-negative meningitis often leads to prolonged dual antibiotic and antiviral therapies, which may be associated with nosocomial complications [114,131 & ].

Adjunctive treatments are designed to reduce secondary inflammation in ABM and decrease the morbidity associated with CNS tissue damage. Inflammation is associated with secondary complications of ABM, including death, deafness, stroke, epilepsy and learning difficulties [91,131 & , [132] [133] [134] . Delayed cerebral thrombosis is a rare complication of ABM that can occur up to 2 weeks postadmission [135, 136] .

In hospitals in high-income settings, patients presenting with suspected pneumococcal meningitis should receive adjunctive dexamethasone to reduce mortality [90, 137] . In low-income settings, dexamethasone is only indicated in cases of suspected S. suis meningitis in Southeast Asia to reduce deafness [137, 138] . In other settings, particularly in Low and Middle Income Countries in Africa, dexamethasone is ineffective and should not be given [139] .

Other previously tested adjuncts, including hypothermia and glycerol, have been shown to be potentially harmful and should not be administered [140, 141] .

Empirical antibiotic treatment in most centres for suspected ABM is the third-generation cephalosporin, ceftriaxone [92] . However, bacterial lysis by ceftriaxone releases DAMPs that may prolong damaging inflammation even as bacteria killed [88] . Research in animal models has strongly suggested bacteriostatic antibiotics are associated with less CNS inflammation and improve outcomes [142] . In clinical practice, there are little data to suggest different clinical outcomes occur between bacteriostatic vs. bactericidal antibiotics [143] . As such, there are continued efforts to develop alternatives that reduce sequalae in survivors. A phase 2 clinical trial evaluating the adjunctive use of a nonlytic antibiotic, daptomycin, for pneumococcal meningitis is currently underway (ClinicalTrials.gov identifier NCT03480191). Adjunctive administration of daptomycin may dampen the inflammatory effects of ceftriaxone through currently unknown mechanisms [144] .

The damaging coagulation and fibrinolytic cascade in CSF are triggered partly by excess complement C5 [98]. Inhibition of C5 improved outcomes in a murine model, clinical trials of C5 antagonists are currently underway [145] .

Newer therapeutic agents with intriguing survival data in animal models are not yet in clinical trials. These include DNAse-1, targeted at disrupting ineffective NETosis, the possible neuroprotective effects of metformin, and matrix-metalloproteinase inhibitors targeted on preventing enzymatic tissue breakdown [83 && , [146] [147] [148] . Proposed adjunctive antipneumococcal therapy includes targeting pneumolysin and P4, a pneumococcal peptide that may inhibit replication [149, 150] .

Community-acquired bacterial meningitis presents ongoing formidable epidemiological and clinical challenges. The ability of meningitis-causing pathogens to evolve in the ecological niche of the nasopharynx during carriage, and escape serotypespecific vaccines has led to new strategies to eliminate disease carriage through serotype-independent vaccination. The outcome of CNS host-pathogen interactions determines clinical sequelae, influenced by host genetic susceptibility.

CSF analysis is essential to make a diagnosis of ABM, leukocyte count remains the most effective predictor of ABM over newer models. 

There are no conflicts of interest. 

Characteristics of invasive pneumococcal disease (IPD) caused by emerging serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) in England; prospective observational cohort study

COVID-19 pandemic and its consequences disrupt epidemiology of enterovirus meningitis

Effect of pneumococcal conjugate vaccines on pneumococcal meningitis

The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations

Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15

The effect of HIV infection on adult meningitis in Indonesia: a prospective cohort study

The impact of HIV on meningitis as seen at a South African Academic Hospital

Incidence of invasive pneumococcal disease in immunocompromised patients: a systematic review and metaanalysis

Universal screening versus risk-based protocols for antibiotic prophylaxis during childbirth to prevent early-onset group B streptococcal disease: a systematic review and metaanalysis

Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study

Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the sustainable development goals

Defeating bacterial meningitis by 2030

Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality

Community-acquired bacterial meningitis in adults in the Netherlands, 2006-14: a prospective cohort study

Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination

Incidence of paediatric pneumococcal meningitis and emergence of new serotypes: a time-series analysis of a 16-year French national survey

Resurgence of pneumococcal meningitis in Europe and Northern America

Rapid increase in nonvaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study

The changing epidemiology of invasive pneumococcal disease after PCV13 vaccination in a country with intermediate vaccination coverage

Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: a phase 2, randomized, controlled, observer-blind study

Efficacy, safety and immunogenicity of a pneumococcal protein-based vaccine co-administered with 13-valent pneumococcal conjugate vaccine against acute otitis media in young children: a phase IIb randomized study

Preclinical development of virulence attenuated Streptococcus pneumoniae strains able to enhance protective immunity against pneumococcal infection

Prevention and control of meningococcal disease: updates from the Global Meningococcal Initiative in Eastern Europe

Meningococcal disease and control in China: findings and updates from the Global Meningococcal Initiative (GMI)

Serogroup C Neisseria meningitidis disease epidemiology, seroprevalence, vaccine effectiveness and waning immunity, England, 1998/99 to 2015/16

Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study

Impact of MenAfriVac in nine countries of the African meningitis belt, 2010-15: an analysis of surveillance data

Emergence and genomic diversification of a virulent serogroup W:ST-2881(CC175) Neisseria meningitidis clone in the African meningitis belt

Weekly feedback bulletin on cerebrospinal meningitis

Vaccination of infants with meningococcal group B vaccine (4CMenB) in England

Declining incidence of Haemophilus influenzae type b disease since introduction of vaccination

Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates

Incidence and aetiology of bacterial meningitis among children aged 1-59 months in South Asia: systematic review and meta-analysis

Elimination of Haemophilus influenzae type b (Hib) disease from the Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study

One hypervirulent clone, sequence type 283, accounts for a large proportion of invasive Streptococcus agalactiae isolated from humans and diseased tilapia in Southeast Asia

Maternal colonization with Group B Streptococcus and serotype distribution worldwide: systematic review and meta-analyses

Rapid detection of the 'highly virulent' group B Streptococcus ST-17 clone

Group B streptococcal colonization, molecular characteristics, and epidemiology

Pan-GWAS of Streptococcus agalactiae highlights lineage-specific genes associated with virulence and niche adaptation

Streptococcal serine-rich repeat proteins in colonization and disease

The Italian arm of the PREPARE study: an international project to evaluate and license a maternal vaccine against Group B Streptococcus

Global perspectives on immunization during pregnancy and priorities for future research and development: an international consensus statement

Group B Streptococcus vaccination in pregnant women with or without HIV in Africa: a nonrandomised phase 2, open-label, multicentre trial

A vaccine against Group B Streptococcus: recent advances

Microinvasion by Streptococcus pneumoniae induces epithelial innate immunity during colonisation at the human mucosal surface

First data showing S. pneumoniae subverting the mucosal epithelium and the associated innate immune response

Perspective of a pediatrician: shared pathogenesis of the three most successful pathogens of children

Benzalkonium tolerance genes and outcome in Listeria monocytogenes meningitis

Community-acquired group B streptococcal meningitis in adults

Olfactory nerve-a novel invasion route of Neisseria meningitidis to reach the meninges

Pneumococcal carriage results in ganglioside-mediated olfactory tissue infection

Inflammation as a modulator of host susceptibility to pulmonary influenza, pneumococcal, and co-infections

Temperature triggers immune evasion by Neisseria meningitidis

Inflammation induced by influenza virus impairs human innate immune control of pneumococcus

Influenza increases invasive meningococcal disease risk in temperate countries

Epidemiology of influenza and meningococcal meningitis in parallel showing peaks of influenza are followed by outbreaks of meningococcal meningitis

Bypassing the blood-brain barrier

Pneumococcal encounter with the blood-brain barrier endothelium

Characterisation of regulatory T cells in nasal associated lymphoid tissue in children: relationships with pneumococcal colonization

Laminin receptor initiates bacterial contact with the blood brain barrier in experimental meningitis models

pIgR and PECAM-1 bind to pneumococcal adhesins RrgA and PspC mediating bacterial brain invasion

New strategy is needed to prevent pneumococcal meningitis

Olfactory ensheathing cells as putative host cells for Streptococcus pneumoniae: evidence of bacterial invasion via mannose receptor-mediated endocytosis

Streptococcus pneumoniae resists intracellular killing by olfactory ensheathing cells but not by microglia

Nasal colonization with Streptococcus pneumoniae includes subpopulations of surface and invasive pneumococci

Free sialic acid acts as a signal that promotes Streptococcus pneumoniae invasion of nasal tissue and nonhematogenous invasion of the central nervous system

Genomic pneumococcal load and CSF cytokines are not related to outcome in Malawian adults with meningitis

Transcriptome analysis of human brain microvascular endothelial cells response to Neisseria meningitidis and its antigen MafA using RNA-seq

Double deficiency of toll-like receptors 2 and 4 alters long-term neurological sequelae in mice cured of pneumococcal meningitis

Neisseria meningitidis elicits a proinflammatory response involving IkappaBzeta in a human blood-cerebrospinal fluid barrier model

Upregulation of CBP by PLY can cause permeability of blood-brain barrier to increase meningitis

Corticosteroids for acute bacterial meningitis

Neurological sequelae of adult meningitis in Africa: a systematic literature review

Management of acute meningitis

Blood-brain barrier pathology and CNS outcomes in Streptococcus pneumoniae meningitis

Complement factor H contributes to mortality in humans and mice with bacterial meningitis

Data showing inhibition of C5 improves survival in murine meninigits. Data underpinning current trial of C5 inhibitors in patients

The early adaptive immune response in the pathophysiological process of pneumococcal meningitis

Cerebrospinal fluid prostaglandins, interleukin 1 beta, and tumor necrosis factor in bacterial meningitis. Clinical and laboratory correlations in placebo-treated and dexamethasonetreated patients

CSF levels of elongation factor Tu is associated with increased mortality in Malawian adults with Streptococcus pneumoniae meningitis

First dual host-pathogen CSF proteome, showing bacterial proteins correlate with clinical outcome, potentially by inhibiting neutrophil-mediated killing of bacteria

Dexamethasone in adults with bacterial meningitis

Corticosteroids for acute bacterial meningitis

Mechanisms of dexamethasone-mediated inhibition of Toll-like receptor signaling induced by Neisseria meningitidis and Streptococcus pneumoniae

Joint sequencing of human and pathogen genomes reveals the genetics of pneumococcal meningitis

Landmark study on host-pathogen GWAS showing host genetic associations with poor clinical outcomes

Hypervirulent pneumococcal serotype 1 harbours two pneumolysin variants with differential haemolytic activity

Genome-wide association analyses of invasive pneumococcal isolates identify a missense bacterial mutation associated with meningitis

Genetic variation in Neisseria meningitidis does not influence disease severity in meningococcal meningitis

In vivo dual RNA-seq reveals that neutrophil recruitment underlies differential tissue tropism of Streptococcus pneumoniae

Key study showing differential tissue tropism and mediation of neutrophil recruitment by S. pneumoniae

Capacity to utilize raffinose dictates pneumococcal disease phenotype

Time-resolved dual RNA-seq reveals extensive rewiring of lung epithelial and pneumococcal transcriptomes during early infection

An in vivo atlas of host-pathogen transcriptomes during Streptococcus pneumoniae colonization and disease

Murine and bacterial transcriptomes at different disease sites

In vivo proteomics identifies the competence regulon and AliB oligopeptide transporter as pathogenic factors in pneumococcal meningitis

Coiled-coil domain containing 3 (CCDC3) represses tumor necrosis factor-alpha/nuclear factor kappaBinduced endothelial inflammation

Systematic review and validation of diagnostic prediction models in patients suspected of meningitis

Prediction of outcome from adult bacterial meningitis in a high-HIV-seroprevalence, resource-poor setting using the Malawi Adult Meningitis Score (MAMS)

Incidence, aetiology, and sequelae of viral meningitis in UK adults: a multicentre prospective observational cohort study

Computed tomography of the head before lumbar puncture in adults with suspected meningitis

Effect of delayed lumbar punctures on the diagnosis of acute bacterial meningitis in adults

Lumbar puncture performed promptly or after neuroimaging in acute bacterial meningitis in adults: a prospective national cohort study evaluating different guidelines

Cranial imaging before lumbar puncture in adults with community-acquired meningitis: clinical utility and adherence to the Infectious Diseases Society of America Guidelines

Cranial computed tomography, lumbar puncture, and clinical deterioration in bacterial meningitis: a nationwide cohort study

The UK joint specialist societies guideline on the diagnosis and management of acute meningitis and meningococcal sepsis in immunocompetent adults

ESCMID guideline: diagnosis and treatment of acute bacterial meningitis

Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis

Accuracy of real-time PCR, Gram stain and culture for Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus influenzae meningitis diagnosis

Advances in molecular diagnostic testing for central nervous system infections

Clinical metagenomic sequencing for diagnosis of meningitis and encephalitis

First report of the clinical utility of NGS for the diagnosis of culture negative meningitis

Impact of an evidence-based guideline on the management of community-acquired bacterial meningitis: a prospective cohort study

Denis B Goal directed therapy for suspected acute bacterial meningitis in adults and adolescents in sub-Saharan Africa

Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae in children with acute bacterial meningitis in Mozambique: implications for a national immunization strategy

Invasive Streptococcus pneumoniae in children

Molecular epidemiology and evolution of Haemophilus influenzae

Mortality in adult patients with culture-positive and culture-negative meningitis in the Botswana national meningitis survey: a prevalent cohort study

Data highlighting the excessive mortality from bacterial meningitis in Africa

Long-term neurologic and cognitive outcome and quality of life in adults after pneumococcal meningitis

Arterial cerebrovascular complications in 94 adults with acute bacterial meningitis

Delayed cerebral thrombosis after initial good recovery from pneumococcal meningitis: past as prologue: delayed stroke as a parainfectious process of bacterial meningitis?

Delayed cerebral thrombosis complicating pneumococcal meningitis: an autopsy study

Delayed cerebral thrombosis in bacterial meningitis: a prospective cohort study

Adjunctive dexamethasone in bacterial meningitis: a meta-analysis of individual patient data

Dexamethasone in Vietnamese adolescents and adults with bacterial meningitis

Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa

Glycerol adjuvant therapy in adults with bacterial meningitis in a high HIV seroprevalence setting in Malawi: a double-blind, randomised controlled trial

Induced hypothermia in severe bacterial meningitis: a randomized clinical trial

Evaluation of ceftriaxone, vancomycin and rifampicin alone and combined in an experimental model of meningitis caused by highly cephalosporin-resistant Streptococcus pneumoniae ATCC 51916

Busting the myth of 'static vs cidal': a systemic literature review

Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis

Adjuvant treatment with dexamethasone plus anti-C5 antibodies improves outcome of experimental pneumococcal meningitis: a randomized controlled trial

Metformin mediates neuroprotection and attenuates hearing loss in experimental pneumococcal meningitis

A randomised double blind placebo controlled phase 2 trial of adjunctive aspirin for tuberculous meningitis in HIV-uninfected adults

Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis

Augmented passive immunotherapy with P4 peptide improves phagocyte activity in severe sepsis

Infection of zebrafish embryos with live fluorescent Streptococcus pneumoniae as a real-time pneumococcal meningitis model